Dr. James A. Bianco

• 
  news.prnewswire.com/DisplayReleaseContent.aspx?ACCT=104 - [Cached Version]
  Published on: 2/5/2009    Last Visited: 2/5/2009  

  "We are pleased that almost all of the remaining preferred shareholders were willing to trade in their securities and enable CTI to avoid their redemption rights and dividend payments, saving the company approximately $6.6 million over the next 6 months, for a meaningful equity position in the Company upon their conversion into common stock," noted James A. Bianco
  
  , M.D., CEO of CTI.

• 
  seattlepi.nwsource.com/opinion/364018_health22.html - [Cached Version]
  Last Visited: 5/22/2008  

  JAMES A. BIANCOGUEST COLUMNIST
  ...
  James A. Bianco is president and CEO of Cell Therapeutics Inc.

• 
  www.corporate-ir.net/ireye/ir_site.zhtml?ticker=CTIC&sc - [Cached Version]
  Published on: 11/29/2006    Last Visited: 3/7/2007  

  "Dr. Telling's considerable pharmaceutical company experience and extensive industry background will be invaluable to CTI as we grow our commercial operations," said James A. Bianco, M.D., President and CEO of CTI.
  ...
  In addition to Telling, CTI's Board of Directors includes Phillip M. Nudelman, Ph.D., Chairman of the Board, President and Chief Executive of The Hope Heart Institute and former President and CEO of Group Health Cooperative; Vartan Gregorian, Ph.D., President of Carnegie Corporation of New York; Mary O. Mundinger, D.P.H., Dean and Professor, School of Nursing and Associate Dean, Faculty of Medicine, Columbia University; John H. Bauer, former EVP of Finance for Nintendo of America, Inc.; James A. Bianco, M.D., President and CEO of CTI, and Jack W. Singer, M.D., Chief Medical Officer of CTI.

• 
  www.genengnews.com/articles/chitem.aspx?aid=2109&chid=0 - [Cached Version]
  Published on: 5/1/2007    Last Visited: 12/10/2007  

  James A. Bianco, M.D.
  
  CEO and President, Cell Therapeutics
  
  Scientists' biggest stumbling block is not making the transition from scientific founder to a business person, according to Dr. Bianco.After 16 years as president and CEO, he says, "companies change as they grow, and the executive who may be excellent at leading a company of less than 100 people could be horrible at leading a company of more than 500."
  
  His goal has been to expand his knowledge base to understand everything that affects the company, including financial, legal, and marketing issues.For example, he says, "We have a CFO, but I was involved in all the financial issues so I could understand them."Developing a broader knowledge base "helps prevent the company from being under-resourced or over-leveraged," he adds."That's a character trait of a good leader."

• 
  www.TalkProgress.com/news/118/text/javascript - [Cached Version]
  Published on: 12/24/2008    Last Visited: 12/24/2008  

  Dr. James A. Bianco Joins Nakea's Board of Directors
  
  SEATTLE, May 1, 2008 — Nakea, LLC., a leader in the development of advanced website management tools, announced today the addition of Dr. James A. Bianco to the company's newly formed Board of Directors.

• 
  www.biohealthinvestor.com/tag/ctic - [Cached Version]
  Last Visited: 10/6/2009  

  James A. Bianco, M.D., Chief Executive Officer of CTI is quoted, "We are pleased that the PIX 301 EXTEND trial of pixantrone demonstrated a long-lasting clinical benefit in this heavily pretreated relapsed/refractory group of patients with aggressive NHL and look forward to completing the New Drug Application submission later this month.

• 
  www.powerlineworld.com/News.aspx?id=134519517&IQ=health - [Cached Version]
  Last Visited: 8/26/2009  

  James Bianco, CEO of CTI, said: "The FDA's acceptance to file our pixantrone NDA represents a significant milestone for CTI and for patients with relapsed and refractory aggressive non-Hodgkin's lymphoma.

• 
  www.sec.gov/Archives/edgar/data/891293/0001193125-04-06 - [Cached Version]
  Published on: 4/19/2004    Last Visited: 7/27/2004  

  The current terms of office of the Class II directors, Dr. Max E. Link, Dr. James A. Bianco and Dr. Vartan Gregorian expire at the 2005 Annual Meeting.
  ...
  James A. Bianco, M.D.
  ...
  Dr. Bianco is our principal founder and has been our president and chief executive officer since February 1992 and one of our directors since our inception in September 1991.Prior to founding CTI, Dr. Bianco was an assistant professor of medicine at the University of Washington, Seattle, and an assistant member in the clinical research division of the Fred Hutchinson Cancer Research Center, the world's largest bone marrow transplant center.From 1990 to 1992, Dr. Bianco was the director of the Bone Marrow Transplant Program at the Veterans Administration Medical Center in Seattle.Dr. Bianco received his B.S. degree in biology and physics from New York University and his M.D. from Mount Sinai School of Medicine.Dr. Bianco is the brother of Louis A. Bianco, our executive vice president, finance and administration.

• 
  www.stockhouse.com/comp_info.asp?symbol=CTIC&table=LIST - [Cached Version]
  Last Visited: 8/16/2007  

  James A. Bianco M.D, Presi.; C.E.O.,

• 
  pharma.immunodefence.com/2006/11/seattle_biotech_firm_h - [Cached Version]
  Published on: 1/1/2006    Last Visited: 5/13/2007  

  James Bianco, chief executive of the Seattle company, said the deaths do not appear related to any safety problems with its drug, Xyotax.
  
  In an interview, Bianco would not say how many patients enrolled have died among the 200 women with lung cancer.But he acknowledged there were more deaths in the group receiving Xyotax than another receiving a standard chemotherapy drug.Further analysis is needed to sort out the reasons, he said.
  
  Bianco said most of the deaths have been attributed to disease progression , meaning the advancement of the patient's cancer.The study's patients have advanced lung cancer, with a life expectancy of 8 to 10 weeks.
  ...
  Bianco said the company expects to revise the study when it resumes, to focus on women with normal estrogen levels.He said earlier that Xyotax studies had found a better effect in such women.
  
  Also, said Bianco, "Some of the women in the trial are entering when they are sicker than they probably should be."
  
  The halted trial isn't the first in the company's history.In October 2003, it halted a Xyotax trial in lung cancer and reduced the dose, after "a handful" of patients suffered premature deaths when their infection-fighting white blood cells were wiped out.
  
  This time, Bianco said, his company is using a lower dose from the start, and it thinks the premature deaths are not related to drug toxicity.
  
  Bianco said the delay will not affect the company's newly signed partnership with Swiss drug giant Novartis.
  
  The news was released after markets had closed.

Page:  1 2 3 4 5